The US Food and Drug Administration (FDA) has approved the use of Aduhelm, a new drug for the treatment of Alzheimer’s, the first to directly treat the “fundamental” effects of this disease.

As reported by the FDA in a statement, it is also the first new treatment against Alzheimer’s that the US administration has approved against this degenerative disease that affects over 6 million people in the country.

In March 2019, in the last phase of clinical trials with the drug, involving 3,000 patients, there was a pause in the trials when analysis showed that, given it as a monthly drink, it was no better at slowing down cognitive decline than any placebo.

The approval of this drug has been accelerated because, according to the FDA, it provides a “significant therapeutic advance” compared to other treatments, by reducing the “beta amyloid” cells in the brain, which are a sign of the disease, and therefore considers it ” reasonable “to expect a significant benefit for Alzheimer’s patients.